Table 3.

Univariate log-rank analyses.

Parameters	Category	DSS		MeFS
		HR (95% CI)	p– value	HR (95% CI)	p– value
Primary tumor (T)	T1 vs. T2 vs. T3-T4	2.159 (1.072– 4.350)	0.031*	4.119 (2.806– 6.045)	<0.001*
Nodal status (N)	N0 vs. N1-N2	3.937 (1.547– 10.021)	0.004*	4.959 (2.847– 8.638)	<0.001*
Stage	Stage I vs. Stage II– Stage III	4.170 (1.213– 14.337)	0.023*	10.061 (3.643– 27.784)	<0.001*
Skp2 Exp.	Continuous	1.018 (1.009– 1.027)	0.009*	1.013 (1.008– 1.017)	<0.001*
MacroH2A1.1 Exp.	Continuous	0.988 (0.978– 0.998)	0.014*	0.990 (0.985– 0.995)	<0.001*
MacroH2A1.2 Exp.	Continuous	0.987 (0.976– 0.997)	0.013*	0.990 (0.985– 0.995)	<0.001
CDK8 Exp.	Continuous	1.011 (1.004– 1.018)	0.001*	1.008 (1.004– 1.012)	0.001*
Skp2 Exp.	Low (<median)	4	0.0040*	19	0.0005*
	High (>=median)	15		42
MacroH2A1.1 Exp.	Low (<median)	14	0.0239*	38	0.0307*
	High (>=median)	5		23
MacroH2A1.2 Exp.	Low (<median)	13	0.0361*	42	0.0002*
	High (>=median)	6		19
CDK8 Exp.	Low (<median)	4	0.0017*	20	0.0007*
	High (>=median)	15		41

DSS, disease-specific survival; MeFS, metastasis-free survival;

^*Statistically significant